Cargando…

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

PURPOSE: Cardiovascular and metabolic adverse events are costly to treat, and their incidence is increased amongst people with schizophrenia, with different rates observed for second-generation antipsychotics. To inform treatment choice, this study sought to estimate the lifetime costs associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kearns, Benjamin, Cooper, Katy, Cantrell, Anna, Thomas, Chloe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829121/ https://www.ncbi.nlm.nih.gov/pubmed/33505160 http://dx.doi.org/10.2147/NDT.S282856

Ejemplares similares

The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model
por: Kearns, Benjamin, et al.
Publicado: (2022)

Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia
por: Kakunje, Anil, et al.
Publicado: (2018)

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
por: Grajales, Diana, et al.
Publicado: (2019)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder
por: Doane, Michael J., et al.
Publicado: (2022)

Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies
por: Panariello, Fabio, et al.
Publicado: (2011)

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia
por: Khasawneh, Fadi T., et al.
Publicado: (2014)

Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment
por: Khandker, Rezaul, et al.
Publicado: (2022)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: A narrative review
por: Zhou, Ruqin, et al.
Publicado: (2022)

Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children
por: Bahr, S M, et al.
Publicado: (2015)

Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
por: Bak, Maarten, et al.
Publicado: (2021)

Altered gene expression in antipsychotic-induced weight gain
por: Crespo-Facorro, Benedicto, et al.
Publicado: (2019)

Combination approaches to reduce weight-gain induced by antipsychotics
por: Hofer, A.
Publicado: (2021)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Use of Conventional Antipsychotics and the Cost of Treating Schizophrenia
por: Lyu, Ramon R., et al.
Publicado: (2001)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia
por: Wei, Yue, et al.
Publicado: (2022)

Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events
por: Hara, Takashi, et al.
Publicado: (2020)

Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events
por: Hara, Takashi, et al.
Publicado: (2021)

Successful Use of Add - On Topiramate for Antipsychotic - Induced Weight Gain
por: Shivakumar, Venkataram, et al.
Publicado: (2012)

Youth, Caregiver, and Prescriber Experiences of Antipsychotic-Related Weight Gain
por: Murphy, Andrea Lynn, et al.
Publicado: (2013)

The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
por: Bretler, Tali, et al.
Publicado: (2019)

The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
por: Libowitz, Mark R., et al.
Publicado: (2021)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia
por: Hatano, Masakazu, et al.
Publicado: (2017)

Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis
por: Racz, Rebecca, et al.
Publicado: (2018)

Efficacy of betahistine in counteracting second-generation antipsychotics-induced weight gain: A meta-analysis with trial sequential analysis
por: Soliman, Y., et al.
Publicado: (2023)

Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics
por: Naderyan Fe'li, Shadi, et al.
Publicado: (2019)

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
por: García-Ruiz, Antonio J, et al.
Publicado: (2012)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons
por: Sahlberg, Marie, et al.
Publicado: (2015)

Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics
por: Evoy, Kirk E, et al.
Publicado: (2019)

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
por: Bak, Maarten, et al.
Publicado: (2014)

The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse
por: Morgan, Andrew P., et al.
Publicado: (2014)

Risk of weight gain for specific antipsychotic drugs: a meta-analysis
por: Spertus, Jacob, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v8edehjkj1dnmm1uheetne0boc